{"id":"hld200","safety":{"commonSideEffects":[{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Anemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By inhibiting histone deacetylase activity, HLD200 prevents the removal of acetyl groups from histone proteins, leading to increased histone acetylation and altered chromatin structure. This results in changes to gene expression patterns, particularly affecting genes involved in cell proliferation and differentiation. The drug is being developed for hematologic malignancies where HDAC inhibition has shown therapeutic potential.","oneSentence":"HLD200 is a histone deacetylase (HDAC) inhibitor that modulates gene expression by blocking HDAC enzymes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:50.032Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Peripheral T-cell lymphoma (PTCL)"}]},"trialDetails":[{"nctId":"NCT06431256","phase":"PHASE3","title":"Efficacy, Safety & Pharmacokinetic (PK) Study of HLD200 in Children Aged 4-5 Years With ADHD","status":"TERMINATED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2024-09-13","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":26},{"nctId":"NCT01907360","phase":"PHASE1, PHASE2","title":"Pharmacokinetics of HLD200 in Children and Adolescents With ADHD","status":"COMPLETED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2013-08","conditions":"Attention-Deficit Hyperactivity Disorder","enrollment":29},{"nctId":"NCT02493777","phase":"PHASE3","title":"A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Classroom Setting","status":"COMPLETED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2015-07","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":125},{"nctId":"NCT02520388","phase":"PHASE3","title":"A Pivotal Efficacy Trial to Evaluate HLD200 in Children With ADHD in a Naturalistic Setting","status":"COMPLETED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2015-08","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":163},{"nctId":"NCT02255513","phase":"PHASE3","title":"A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHD","status":"COMPLETED","sponsor":"Ironshore Pharmaceuticals and Development, Inc","startDate":"2014-05","conditions":"Attention Deficit Hyperactivity Disorder","enrollment":43}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":12,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["methylphenidate hydrochloride (MPH)"],"phase":"phase_3","status":"active","brandName":"HLD200","genericName":"HLD200","companyName":"Ironshore Pharmaceuticals and Development, Inc","companyId":"ironshore-pharmaceuticals-and-development-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HLD200 is a histone deacetylase (HDAC) inhibitor that modulates gene expression by blocking HDAC enzymes. Used for Peripheral T-cell lymphoma (PTCL).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}